Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia. / Stinson, Sara E; Jonsson, Anna E.; Alzola, Ierai Fernández de Retana; Lund, Morten A V; Frithioff-Bøjsøe, Christine; Holm, Louise Aas; Fonvig, Cilius E.; Pedersen, Oluf; Ängquist, Lars; Sørensen, Thorkild I A; Holst, Jens J; Christiansen, Michael; Holm, Jens-Christian; Hartmann, Bolette; Hansen, Torben.
I: Journal of Clinical Endocrinology and Metabolism, Bind 107, Nr. 6, 2022, s. 1569–1576.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not hyperglycemia
AU - Stinson, Sara E
AU - Jonsson, Anna E.
AU - Alzola, Ierai Fernández de Retana
AU - Lund, Morten A V
AU - Frithioff-Bøjsøe, Christine
AU - Holm, Louise Aas
AU - Fonvig, Cilius E.
AU - Pedersen, Oluf
AU - Ängquist, Lars
AU - Sørensen, Thorkild I A
AU - Holst, Jens J
AU - Christiansen, Michael
AU - Holm, Jens-Christian
AU - Hartmann, Bolette
AU - Hansen, Torben
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
PY - 2022
Y1 - 2022
N2 - CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. The role of glucagon in pediatric overweight/obesity remains unclear.OBJECTIVE: We examined whether fasting concentrations of glucagon are elevated in youth with overweight/obesity and whether this associates with cardiometabolic risk profiles.METHODS: Analyses were based on the cross-sectional HOLBAEK Study, including 6-19-year-old children and adolescents with overweight/obesity from an obesity clinic group (n = 2154) and a population-based group with normal weight (n = 1858). Fasting concentrations of plasma glucagon and cardiometabolic risk outcomes were assessed, multiple linear and logistic regressions models were performed.RESULTS: The obesity clinic group had higher glucagon concentrations than the population-based group (P < 0.001). Glucagon positively associated with BMI standard deviation score (SDS), waist, body fat %, liver fat %, alanine transaminase (ALT), high-sensitivity C-reactive protein, homeostasis model assessment of insulin resistance, insulin, C-peptide, LDL-C, triglycerides, SDS of diastolic and systolic blood pressure, and was inversely associated with fasting glucose. The inverse relationship between glucagon and glucose was attenuated in individuals with high BMI SDS and high fasting insulin. Glucagon was associated with a higher prevalence of insulin resistance, increased ALT, dyslipidemia, and hypertension, but not with hyperglycemia. Glucagon was positively associated with fasting total glucagon-like peptide-1.CONCLUSIONS: Compared to normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corresponded to worsened cardiometabolic risk outcomes, except for hyperglycemia. This suggests hyperglucagonemia in youth may precede impairments in glucose regulation.
AB - CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. The role of glucagon in pediatric overweight/obesity remains unclear.OBJECTIVE: We examined whether fasting concentrations of glucagon are elevated in youth with overweight/obesity and whether this associates with cardiometabolic risk profiles.METHODS: Analyses were based on the cross-sectional HOLBAEK Study, including 6-19-year-old children and adolescents with overweight/obesity from an obesity clinic group (n = 2154) and a population-based group with normal weight (n = 1858). Fasting concentrations of plasma glucagon and cardiometabolic risk outcomes were assessed, multiple linear and logistic regressions models were performed.RESULTS: The obesity clinic group had higher glucagon concentrations than the population-based group (P < 0.001). Glucagon positively associated with BMI standard deviation score (SDS), waist, body fat %, liver fat %, alanine transaminase (ALT), high-sensitivity C-reactive protein, homeostasis model assessment of insulin resistance, insulin, C-peptide, LDL-C, triglycerides, SDS of diastolic and systolic blood pressure, and was inversely associated with fasting glucose. The inverse relationship between glucagon and glucose was attenuated in individuals with high BMI SDS and high fasting insulin. Glucagon was associated with a higher prevalence of insulin resistance, increased ALT, dyslipidemia, and hypertension, but not with hyperglycemia. Glucagon was positively associated with fasting total glucagon-like peptide-1.CONCLUSIONS: Compared to normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corresponded to worsened cardiometabolic risk outcomes, except for hyperglycemia. This suggests hyperglucagonemia in youth may precede impairments in glucose regulation.
U2 - 10.1210/clinem/dgac108
DO - 10.1210/clinem/dgac108
M3 - Journal article
C2 - 35213713
VL - 107
SP - 1569
EP - 1576
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 6
ER -
ID: 300012430